Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MBD2 deficiency does not accelerate p53 mediated lymphomagenesis.

Owen James Sansom1, Stefan Mark Bishop, Adrian Bird

  • 1Mammalian Genetics, Cardiff School of Biosciences, University of Cardiff, Museum Avenue, PO Box 911, Cardiff CF10 3US, UK.

Oncogene
|March 1, 2005
PubMed
Summary

Loss of methyl-binding domain protein 2 (Mbd2) does not accelerate lymphomagenesis in mice, unlike DNA methyltransferase 1 (DNMT1). This suggests Mbd2 is a safer therapeutic target for cancer than DNMT1.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MeCP2 requires interactions with nucleosome linker DNA to read chromatin DNA methylation.

Nature communications·2026
Same author

Modelling transcription with explainable AI uncovers context-specific epigenetic gene regulation at promoters and gene bodies.

PLoS genetics·2025
Same author

Cohesin as an essential disruptor of chromosome organization.

Molecular cell·2025
Same author

MeCP2 binds to methylated DNA independently of phase separation and heterochromatin organisation.

Nature communications·2024
Same author

Loss of CpG island immunity to DNA methylation induced by mutation.

Epigenetics & chromatin·2023
Same author

Structure of SALL4 zinc finger domain reveals link between AT-rich DNA binding and Okihiro syndrome.

Life science alliance·2023

Area of Science:

  • Epigenetics and Cancer Biology
  • Genomic Instability Research
  • Tumorigenesis Mechanisms

Background:

  • Recent studies link reduced DNA methylation via DNA methyltransferase 1 (DNMT1) to increased genomic instability and lymphomagenesis.
  • Previous research indicated that loss of methyl-binding domain protein 2 (Mbd2) suppresses intestinal tumorigenesis.

Purpose of the Study:

  • To investigate whether Mbd2 deficiency exacerbates lymphomagenesis.
  • To compare the effects of Mbd2 loss versus DNMT1 modulation on lymphomagenesis.
  • To evaluate Mbd2 as a potential therapeutic target in lymphomagenesis.

Main Methods:

  • Intercrossing Mbd2 deficient mice with p53 deficient and p53 heterozygous mice.
  • Assessing lymphomagenesis progression in the generated mouse models.

Related Experiment Videos

  • Comparing outcomes with known effects of DNMT1 modulation.

    • Main Results:

    • Loss of Mbd2 did not accelerate lymphomagenesis in the examined mouse models.
    • The impact of Mbd2 deficiency on lymphomagenesis differs significantly from that of DNMT1.

    Conclusions:

    • Mbd2 deficiency does not promote lymphomagenesis.
    • MBD2 represents a potentially safer therapeutic target for preventing or treating lymphomagenesis compared to DNMT1.